| INTRODUCTION
Acute liver failure (ALF) is a rare and life-threatening condition occurring in patients without pre-existing liver disease. The clinical presentation may be rapidly progressive or insidious with evidence of jaundice, coagulopathy and deranged liver enzymes. The development of clinically apparent hepatic encephalopathy differentiates those patients with severe acute liver injury (ALI) from patients with ALF. 1 Acute liver failure is associated with significant morbidity and mortality. 1 The clinical course and outcome depends upon the underlying aetiology, age of the patient, the period of time over which the disease develops, the extent of liver damage (which are all interrelated) and early institution of supportive care. 1 The most common cause of ALF in the UK, USA and some parts of Europe is paracetamol (acetaminophen) overdose, which may be taken with suicidal intent or follow accidental consumption of excess amounts over time. Elsewhere, viral hepatitis is the most common aetiological agent. However, a significant proportion of acute liver failure cases do not have an identifiable cause; so called non A-E, seronegative or indeterminate hepatitis. Several studies have proposed the existence of hepatotrophic agents beyond those currently recognised, and others have implicated the role of hepatotoxic drugs in leading to this clinical syndrome. Previously, GB Virus C, 2 hepatitis G Virus 3 and TT Virus (TTV) 4 have all been suggested as pathogenic agents, however, true causation has never been substantiated. [5] [6] [7] In this review, we discuss the potential aetiological agents, clinical manifestations, treatments and clinical outcomes in non A-E, seronegative or indeterminate ALF, and highlight significant gaps in current understanding of many areas of this rare condition with the aim to facilitate future studies.
| ME TH ODS
This review was conducted according to PRISMA 8 statement guidelines. MEDLINE (OvidSP), PubMed, EASL (European Association for the Study of Liver) and AASLD (American Association for the Study of Liver Diseases) archives were searched for studies in acute or fulminant, hepatic or liver failure using the terms "non-A non-B" "non-
A, non-B, non-C," "seronegative hepatitis," "non A-E" and "indetermi- 
| Nomenclature
There is widespread variability in the nomenclature used both in clinical practice and research studies to describe causes of acute liver failure not identified by standard diagnostic tests. Historically this disease entity was labelled non-A, non-B hepatitis, and as new viruses were identified non A-E hepatitis became the preferred terminology ( Figure 2 ). This nomenclature suggests the aetiological agent for this condition is an as yet unidentified hepatotrophic virus. More recently, the term 'seronegative hepatitis' has also been used. This terminology recognises the possibility of uncharacterised autoimmune or immune mediated liver injury.
Latterly 'indeterminate hepatitis' has been favoured when the cause of ALF cannot be identified, perhaps covering all potential pathogenic mechanisms of liver injury. Therefore, 'indeterminate hepatitis' will be the preferred term throughout this review.
O'Grady and colleagues 5 proposed modification of the definition for acute liver failure based on the time between jaundice and the development of hepatic encephalopathy: "hyperacute liver failure" occurs when encephalopathy develops within 7 days of the onset of jaundice, 'acute liver failure" when encephalopathy develops within these latter cases usually survive spontaneously, but clinical models to predict the development of encephalopathy are poorly developed.
| Epidemiology
As discussed above, a significant proportion of patients with acute liver failure have no specific cause identified using currently available diagnostic techniques ie indeterminate ALF. A number of centres, predominantly from the Western world, have reported the number of patients diagnosed with indeterminate ALF (Table 1 and Figure 3 ).
In total; the studies included 5027 cases of acute liver failure, with 689 (~20%) incidents of indeterminate causation. There is some inherent heterogeneity between the studies including access to specialist referral units and particular serological tests; therefore, the numbers should be interpreted with caution. It is well recognised that indeterminate acute liver failure is more common in the paediatric than adult population; however, a detailed review of the paediatric literature is out with the scope of this review. In this case, infection was also self-limiting. In addition, Langnas 9 also
proposed parvovirus B19 as a causative agent in a small case series Total Abstracts reviewed as eligible and reviewed (n = 75) F I G U R E 1 Flow diagram of literature search and relevant articles of acute liver failure, all of which were associated with aplastic anaemia. Quite how parvovirus elicits a hepatotoxic effect is not completely understood but may relate to caspase three-mediated apoptosis. 10 
| Undetected paracetamol overdose
The measurement of paracetamol (acetaminophen) adducts in cases of indeterminate ALF has recently been the subject of debate and interest. Paracetamol-protein adducts are formed when NAPQI binds with the amino acid cysteine in cellular proteins after large dose paracetamol ingestion, and are released into the peripheral circulation as a consequence of hepatocyte necrosis, where they can then be detected.
Khandelwal's study confirms and extends the previous reports 21 regarding the use of paracetamol-protein adduct measurement in the diagnostic evaluation of patients with acute liver failure. In this large data set using a refined assay method, paracetamol-protein adducts were detected in 95% of patients with clinically defined paracetamol (Table 2) . 29 These have not been validated in adult patients; however, they may provide a diagnostic framework for consideration of potential cases. was not made, the diagnosis was 'indeterminable' if key diagnostic information was missing, and 'truly indeterminate' if complete diagnostic information was available. 31% were defined as truly indeterminate, making up just 3.3% of acute liver failure cases in the ALFSG registry overall. This figure is lower than that reported in other studies, suggesting that diagnostic techniques as described above do need to be more widely adopted to ensure a correct diagnosis is made.
| Unrecognised idiosyncratic drug reactions and environmental toxins

| Clinical features
Indeterminate hepatitis usually results in subacute liver failure, with the symptoms typically present greater than 4 weeks before the development of encephalopathy. There is a female preponderance reported in all cases series, with a bimodal age distribution. Table 1 records the percentages of patients with indeterminate liver failure contributing to reported cohorts of patients with ALF. The highest reported percentage of patients with indeterminate acute liver failure was reported in Sudan, 13 however, their access to certain diagnostic techniques may be limited. A group from China also reported a higher percentage of patients with indeterminate acute liver failure compared with other studies, 20 however, it must be borne in mind that this study included paediatric patients.
Prodromal symptoms are nonspecific, including fatigue, myalgia and nausea. Often these symptoms can be mistaken for a viral prodrome. Biochemically, these patients demonstrate lower transaminases and higher bilirubin levels, similar to other causes of subacute ALF and in contrast with the high transaminases and lower bilirubin levels seen in hyperacute liver failure, especially paracetamol toxicity. Other clinical features include a lesser degree of coagulopathy, and less renal failure and acidosis when compared with paracetamol toxicity.
The American Acute Liver Failure Study Group has previously described the demographics of patients registered with indeterminate hepatitis on the ALFSG Adult Registry between 1998 and 2014. 37 The main findings are summarised in 
| Association with aplastic anaemia
Indeterminate hepatitis is the most common cause of ALF with associated aplastic anaemia. 39 The presence of aplastic anaemia increases the mortality associated with acute liver failure and may not resolve following transplantation, necessitating post-transplant treatment with immunosuppressive therapy or even haematopoietic cell transplantation. The presence of aplastic anaemia raises the suspicion that a viral aetiology is the cause for indeterminate disease. 9 
| Management
The principle goal of management of acute liver failure (regardless of aetiology) is to achieve metabolic and haemodynamic stability to provide optimal conditions for hepatic regeneration and minimisation of associated complications. Early identification of individuals with a significantly reduced chance of spontaneous survival enhances the provision of successful emergency liver transplantation. The treatment is generally founded on the basic principles applied to other critically unwell patients, with some specific caveats. 40 management of these patients. The main aspects of organ specific supportive management as recommended by EASL and AASLD are compared in Table 4 .
| Medical management
| N-acetylcysteine (NAC)
NAC has complex antioxidant and immunological effects that may benefit individuals with nonparacetamol-related acute liver failure.
Stravitz 41 demonstrated that interleukin-17 was an independent predictor of poor outcome in patients with nonparacetamol ALF;
higher interleukin-17 levels were associated with progression of hepatic encephalopathy and decreased with NAC administration.
However, this survival benefit of NAC seems to be limited to those nonparacetamol patients with Grade I-II encephalopathy. A multicentre prospective double-blind trial of NAC in patients with nonparacetamol ALF was undertaken by the Acute Liver Failure Study Group (ALFSG). 44 The treatment group received NAC via infusion for 72 hours. There was no difference in overall survival at 3 weeks in those patients receiving NAC versus placebo. However, transplant free survival was significantly improved in those patients receiving NAC, but this benefit was largely confined to those patients with a low coma grade (transplant free survival in patients with coma grade I-II; 52% in NAC group versus 30% in placebo group). The authors therefore cautiously advised that NAC be considered for early nonparacetamol ALF but that its use must not delay referral to a transplant centre.
| Corticosteroids
The use of corticosteroid therapy in acute liver failure has been con- This finding was most significant in those with an illness duration of less than 2 weeks. 46 Unfortunately, they did not specify outcomes for different aetiologies and it is therefore hard to evaluate any specific benefit in indeterminate hepatitis. Given the relative lack of robust evidence in indeterminate liver failure, steroid therapy cannot be advocated unless there is significant concern regarding underlying autoantibody negative autoimmune hepatitis.
| Prognostication and emergency liver transplantation
The early identification of individuals with acute liver failure and significantly reduced spontaneous survival with medical therapy is crucial in identifying candidates for emergency liver transplantation. In patients with indeterminate hepatitis on the ALFSG Adult Registry between 1998 and 2013, 57% of patients with indeterminate hepatitis were listed for transplant, with a transplant free survival rate of 27.5%. 47 In the remainder of the western world, the spontaneous (transplant free) survival rate for indeterminate liver failure is also quoted between 20%-25%, in comparison with 65% spontaneous survival in patients with paracetamol induced acute liver failure. 48 Various prognostic criteria are applied throughout the world.
Common features of these models include age and increased severity of liver failure defined by the degree of coagulopathy and jaundice. 40 The Kings College Criteria have traditionally been used in the UK and elsewhere in the western world to predict poor outcome. In patients with a nonparacetamol aetiology such as indeterminate hepatitis, an INR > 6.5 and three or more of the following were predictors of a poor outcome: unfavourable cause (not hepatitis A or B viral infection), jaundice to encephalopathy time greater than 7 days, age less than 10 or more than 40 years, INR more than 3.5 and bilirubin more than 300 lmol/L. In many studies including systematic reviews and meta-analyses, these criteria have consistently demonstrated high specificity but lower sensitivity and negative predictive value. 49 In the UK, the criteria used to list patients for emergency liver transplantation have recently been modified. 50 (not death, the outcome of interest in most prognostic models) in patients with acute liver failure. 52 The Bernal reported that use of transplantation for nonparacetamol liver failure has increased over time, with the proportion of patients undergoing transplantation being higher in nonparacetamol cases compared with paracetamol cases. 53 Survival following transplantation has also increased over time, likely as a result of improvements in surgical, medical and intensive care management. However, in the same cohort, no improvement in transplant free survival was noted over time. Donnelly also recently reported an increase in survival post transplantation for patients with nonparacetamol acute liver failure, with a trend towards improvement in transplant free survival also observed. 48 There is no doubt that transplantation is the only rescue therapy proven to be of benefit in selected patients with severe indeterminate hepatitis, and other treatment options are desperately needed so as not to disadvantage those on the elective liver transplant waiting list.
| Future therapies and strategies
Future work and research should focus on developing large international registries of patients with indeterminate acute liver failure, which may help to identify population based factors associated with the development of the disease, which in turn may point towards a specific aetiological agent or trigger. Such registries may also identify common clinical features allowing earlier diagnosis and prognostication.
"Omic" technologies will likely have a role to play in the future in both the diagnosis and prognosis of indeterminate acute liver failure.
Metabolomics studies a set of metabolites present in biological fluids, and facilitates the discovery of specific metabolic profiles associated with a disease. However, this is a technique still early in clinical application and it is unlikely to be used extensively in the near future. Sequencing and microarray technology may allow the detection of novel viruses. Such technology has already been successful in identifying a virus associated with prostate cancer and novel viral causes of SARS. 54 Although potential viral causes may be identified this way, demonstrating a true causal relationship will be challenging.
Whole exome sequencing has been used in the paediatric population to identify rare causes of ALF in patients who were otherwise labelled as having an indeterminate cause. Causes of ALF identified using this technique include mitochondrial disorders and syndromic cholestasis due to NOTCH2 mutations. 55 Recently, Somasekar used Further research in this field is desperately required, to identify any aetiological agents, develop specific therapy and to reduce the number of patients who require emergency liver transplantation.
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